Plain-English translation of NCT05528133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to radiation therapy for triple negative breast cancer that uses a genetic test of your tumor to guide how much radiation you receive. Instead of using the same radiation dose for everyone, the study is exploring whether tailoring the radiation dose to your tumor's genetics—measured by something called a Radiosensitivity Index—might work better. Researchers will compare this personalized approach to the standard treatment that all patients currently receive.
Triple negative breast cancer is an aggressive form of cancer that doesn't respond to some common treatments, and doctors need better ways to personalize care. This study exists to find out whether using your tumor's genetic profile to customize radiation therapy could improve how well the treatment works and potentially reduce side effects.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo radiation therapy to your breast, tailored based on a genetic test of your tumor. One group will receive personalized radiation doses calculated from the genetic test results, while the other group will receive the standard radiation dose that is given to all patients. You will receive whole breast radiation therapy, and your doctor may also recommend radiation to nearby lymph nodes or an extra boost of radiation to the surgical site, depending on your individual case.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States